{"id":6355,"date":"2015-10-14T10:33:00","date_gmt":"2015-10-14T10:33:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=6355"},"modified":"2021-10-14T10:36:48","modified_gmt":"2021-10-14T10:36:48","slug":"dose-intensified-granulocyte-monocyte-apheresis-in-therapy-refractory-ulcerative-colitis","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/dose-intensified-granulocyte-monocyte-apheresis-in-therapy-refractory-ulcerative-colitis\/","title":{"rendered":"Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis"},"content":{"rendered":"
\n

Caroline Schulthei\u00df<\/a>\u00a01<\/a><\/sup>,\u00a0Ren\u00e9 Weischenberg<\/a>,\u00a0Andrea Herrmann<\/a>,\u00a0Bernhard Haller<\/a>,\u00a0Roland M Schmid<\/a>,\u00a0Wolfgang Reindl<\/a>,\u00a0Wolfgang Huber<\/a>, Artif Organs . 2015 Feb;39(2):187-92<\/p>\n<\/div>\n\n

\n

Dose-intensified GMA as reported in this study provided an encouraging short-term response rate of 70% in patients with moderately to severely active UC not responding to standard steroid or immunomodulator therapy. Although all patients relapsed not later than 16 weeks, GMA might be useful to reduce steroid and immunomodulator usage, or to delay surgery in this patient group.<\/p>\n<\/div>\n\n

\n

(nih.gov)<\/a>https:\/\/pubmed.ncbi.nlm.nih.gov\/24981894\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Caroline Schulthei\u00df\u00a01,\u00a0Ren\u00e9 Weischenberg,\u00a0Andrea Herrmann,\u00a0Bernhard Haller,\u00a0Roland M Schmid,\u00a0Wolfgang Reindl,\u00a0Wolfgang Huber, Artif Organs . 2015 Feb;39(2):187-92 Dose-intensified GMA as reported in this study provided an encouraging short-term response rate of 70% in patients with moderately to severely active UC not responding to standard steroid or immunomodulator therapy. Although all patients relapsed not later than 16 weeks, GMA […]<\/p>\n","protected":false},"template":"","scientific_tags":[429,424,427,428,306],"class_list":["post-6355","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-double-filters","scientific_tags-gma","scientific_tags-platelet-count","scientific_tags-rachmilewitz-index","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":""},"yoast_head":"\nDose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/dose-intensified-granulocyte-monocyte-apheresis-in-therapy-refractory-ulcerative-colitis\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Caroline Schulthei\u00df\u00a01,\u00a0Ren\u00e9 Weischenberg,\u00a0Andrea Herrmann,\u00a0Bernhard Haller,\u00a0Roland M Schmid,\u00a0Wolfgang Reindl,\u00a0Wolfgang Huber, Artif Organs . 2015 Feb;39(2):187-92 Dose-intensified GMA as reported in this study provided an encouraging short-term response rate of 70% in patients with moderately to severely active UC not responding to standard steroid or immunomodulator therapy. Although all patients relapsed not later than 16 weeks, GMA […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/dose-intensified-granulocyte-monocyte-apheresis-in-therapy-refractory-ulcerative-colitis\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-14T10:36:48+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/dose-intensified-granulocyte-monocyte-apheresis-in-therapy-refractory-ulcerative-colitis\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/dose-intensified-granulocyte-monocyte-apheresis-in-therapy-refractory-ulcerative-colitis\/\",\"name\":\"Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2015-10-14T10:33:00+00:00\",\"dateModified\":\"2021-10-14T10:36:48+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/dose-intensified-granulocyte-monocyte-apheresis-in-therapy-refractory-ulcerative-colitis\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/dose-intensified-granulocyte-monocyte-apheresis-in-therapy-refractory-ulcerative-colitis\/","og_locale":"fr_FR","og_type":"article","og_title":"Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis - Adacyte","og_description":"Caroline Schulthei\u00df\u00a01,\u00a0Ren\u00e9 Weischenberg,\u00a0Andrea Herrmann,\u00a0Bernhard Haller,\u00a0Roland M Schmid,\u00a0Wolfgang Reindl,\u00a0Wolfgang Huber, Artif Organs . 2015 Feb;39(2):187-92 Dose-intensified GMA as reported in this study provided an encouraging short-term response rate of 70% in patients with moderately to severely active UC not responding to standard steroid or immunomodulator therapy. Although all patients relapsed not later than 16 weeks, GMA […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/dose-intensified-granulocyte-monocyte-apheresis-in-therapy-refractory-ulcerative-colitis\/","og_site_name":"Adacyte","article_modified_time":"2021-10-14T10:36:48+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/dose-intensified-granulocyte-monocyte-apheresis-in-therapy-refractory-ulcerative-colitis\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/dose-intensified-granulocyte-monocyte-apheresis-in-therapy-refractory-ulcerative-colitis\/","name":"Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2015-10-14T10:33:00+00:00","dateModified":"2021-10-14T10:36:48+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/dose-intensified-granulocyte-monocyte-apheresis-in-therapy-refractory-ulcerative-colitis\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/6355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=6355"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=6355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}